Recent developments include positive clinical updates from breast cancer studies, an exclusive licensing agreement for a gastroparesis treatment candidate, participation in major healthcare conferences, and exploration of a cryptocurrency treasury strategy.

• Processa Pharmaceuticals announced participation in the 44th Annual J.P. Morgan Healthcare Conference in January 2026 [N1].
• The company entered an exclusive licensing agreement with Intact Therapeutics for PCS12852, a potential treatment for gastroparesis, in June 2025 [N8].
• Processa showcased next-generation cancer therapies at the 2025 BIO International Convention and highlighted three accepted abstracts at the 2025 ASCO Annual Meeting [N7].
• Positive clinical updates from breast cancer studies showed that NGC-Cap has reduced toxicity and higher metabolite exposure, leading to a stock price increase in December 2025 [N3][N4].
• The company closed a $5 million public offering with CEO and institutional investor participation in January 2025 [N15].

Processa Pharmaceuticals has demonstrated progress in its clinical programs, notably with NGC-Cap showing reduced toxicity and higher metabolite exposure in breast cancer studies, which has generated positive market interest. The exclusive licensing agreement for PCS12852 expands its pipeline into gastrointestinal disorders. The company's participation in major healthcare conferences and investor events enhances visibility and potential partnership opportunities. Its leadership team's extensive experience in drug development and regulatory affairs supports execution. The company's liquidity position as of late 2025 provides a runway for ongoing development activities. Exploration of a cryptocurrency treasury strategy may offer alternative financial opportunities if managed prudently.

Processa Pharmaceuticals faces significant risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company reported a substantial net loss of $13.56 million in 2025, reflecting ongoing development expenses without revenue generation. Nasdaq has issued deficiency notices related to the company's stock price, requiring a reverse stock split to maintain listing compliance, which may impact investor perception and liquidity. The newly adopted cryptocurrency treasury strategy introduces additional risks related to digital asset volatility, regulatory scrutiny, and cybersecurity threats. Delays or disruptions at the FDA due to staffing or funding issues could further hinder product development timelines. Capital requirements for continued operations may necessitate additional financing, potentially dilutive to shareholders.

Processa Pharmaceuticals' moat is primarily based on its proprietary drug candidates in development, including NGC-Cap and PCS12852, and its regulatory science approach shaped by extensive FDA interactions. The company's leadership team has significant pharmaceutical industry experience, which supports its drug development and regulatory strategy. However, as a clinical-stage company, it faces typical biotech risks such as clinical trial outcomes, regulatory approvals, and capital requirements. The exclusive licensing agreement for PCS12852 and the company's intellectual property portfolio contribute to its competitive positioning. The company's moat is moderate given the early-stage nature of its assets and the competitive pharmaceutical development landscape.

• Regulatory Approval Risks: Delays or failures in obtaining FDA or other regulatory approvals could significantly impact the company's ability to commercialize its drug candidates.
• Nasdaq Listing Compliance: The company has received deficiency notices from Nasdaq due to its stock price falling below the minimum bid price requirement, necessitating a reverse stock split and posing risks to continued listing.
• Financial Losses and Capital Needs: Processa reported a net loss of $13.56 million in 2025 and may require additional capital to fund operations, which could dilute existing shareholders.
• Cryptocurrency Treasury Strategy Risks: The company's exploration of a cryptocurrency treasury strategy involves risks including high price volatility, cybersecurity threats, regulatory uncertainty, and potential financial losses.
• FDA and Government Agency Disruptions: Potential staffing reductions, budget cuts, and policy changes at the FDA and other agencies may delay product development and approvals.

• Processa Pharmaceuticals, Inc. is a Delaware corporation headquartered in Vero Beach, Florida, listed on Nasdaq under ticker PCSA [S1].
• As of April 29, 2026, the company had 2,738,998 shares outstanding [S1].
• The company focuses on pharmaceutical drug development, including next-generation cancer therapies and treatments for gastroparesis [N8][N3][N4].
• Processa has a leadership team with extensive pharmaceutical and biotech experience, including CEO George Ng and Chief Development and Regulatory Officer Dr. Sian Bigora, who transitioned to part-time status effective May 1, 2026 [S1].
• The company has entered an exclusive licensing agreement with Intact Therapeutics for PCS12852, a potential treatment for gastroparesis [N8].
• Processa has presented and showcased its cancer therapies at major industry conferences such as the 44th Annual J.P. Morgan Healthcare Conference and the 2025 BIO International Convention [N1][N7].
• Recent clinical updates from breast cancer studies indicate reduced toxicity and higher metabolite exposure for Processa's NGC-Cap candidate, generating positive market reactions [N3][N4].
• The company closed a $5 million public offering with participation from the CEO and institutional investors in early 2025 [N15].
• Financial figures as of December 31, 2025, include cash and equivalents of approximately $5.54 million, current assets of $5.67 million, current liabilities of $2.24 million, net loss of $13.56 million, and basic and diluted EPS of -$10.36 [S1].
• Liquidity ratios as of December 31, 2025, show a current ratio of 2.54 and a cash ratio of 2.48, indicating a solid short-term liquidity position [S1].
• The company is exploring a cryptocurrency treasury strategy initiated in August 2025, involving investments in digital assets, which introduces new operational and regulatory risks [S2].
• Risks include potential FDA delays due to staffing and funding issues, Nasdaq listing compliance challenges including a reverse stock split to meet minimum bid price requirements, and regulatory uncertainties related to digital asset holdings [S2].